Effectiveness and safety of immunotherapy in advanced NSCLC with pericardial effusions: a global retrospective multicenter study
The Oncologist · 06.08.2026 · 31 (9)
DOI: 10.1093/oncolo/oyag277 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Oncologist, online erschienen am 25.07.2026. Verfasst von Talal El Zarif und 51 weiteren Autor:innen. Beteiligte Einrichtung: Yale University School of Medicine, Department of Internal Medicine, New Haven, CT 06510, United States. Hauptthemen laut MEDLINE: Pericardial Effusion, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
There is limited data on immune checkpoint inhibitor (ICI) use in patients with non-small cell lung cancer (NSCLC) and known pericardial effusions.
Methods
This international multi-center observational retrospective study included patients with advanced NSCLC with or without pericardial effusions receiving ICIs. Immune-related adverse events (irAEs) were graded per CTCAE v5.0. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method. Cox proportional hazards multivariable models assessed the association between survival outcomes and clinicopathologic variables, and an inverse probability of treatment weighting (IPTW) model compared outcomes between the two groups.
Results
A total of 1248 patients with advanced NSCLC treated with ICIs across 13 institutions were included. Of these, 85 patients (6.8%) had pre-existing pericardial effusions. Compared to controls, patients with pericardial effusions were younger (median age 63 vs 67 years, P = .007), diagnosed more frequently with PD-L1 positive tumors (96% vs 76%, P < .001), and had a higher median number of baseline metastatic sites (3 vs 1, P < .001). IrAEs were similar between both groups (42% vs 38%), and no cardiac irAEs occurred in patients with pericardial effusions. PFS (median 5.6 vs 4.6 months, P = .3) and OS (median 10.2 vs 14.7 months, P = .50) were not statistically different between patients with pericardial effusions and the controls, respectively. In both multivariable and IPTW models, pericardial effusions were not associated with PFS or OS.
Conclusions
Among patients with NSCLC and pre-existing pericardial effusions, ICIs demonstrate meaningful clinical benefit similar to those without effusions, with no new cardiac or severe toxicities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Yale University School of Medicine, Department of Internal Medicine, New Haven, CT 06510, United States.
- Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, United States.
- Department of Medical Oncology, Universita Politecnica delle Marche, AOU delle Marche, Ancona 60121, Italy.
- Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK 73104, United States.
- Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, United States.
- Division of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, MD 21287, United States.
ORCID-Profile: Talal El Zarif, Edoardo Garbo, Karl Semaan, Shirly Grynberg, Elias Bou Farhat, Marc Eid, Eddy Saad, Aakash Desai, Chul Kim, Pasi Janne, Abdul Rafeh Naqash
Zitieren
APA
El Zarif, T., Abou Alaiwi, S., Nassar, A. H., Gariazzo, E., Santo, V., Garbo, E., Aldea, M., Paoloni, F., Pannu, S., Semaan, K., Chehab, O., Hoballah, M., Navani, V., Gao, Y., Meyers, D., Stukalin, I., Mittra, A., Li, M., Jones, N., …, & Naqash, A. R. (2026). Effectiveness and safety of immunotherapy in advanced NSCLC with pericardial effusions: a global retrospective multicenter study. The Oncologist, 31(9). https://doi.org/10.1093/oncolo/oyag277
Vancouver
El Zarif T, Abou Alaiwi S, Nassar AH, Gariazzo E, Santo V, Garbo E, et al. Effectiveness and safety of immunotherapy in advanced NSCLC with pericardial effusions: a global retrospective multicenter study. The Oncologist. 2026;31(9). doi:10.1093/oncolo/oyag277
BibTeX
@article{ElZarif2026,
author = {El Zarif, Talal and Abou Alaiwi, Sarah and Nassar, Amin H and Gariazzo, Eleonora and Santo, Valentina and Garbo, Edoardo and Aldea, Mihaela and Paoloni, Francesco and Pannu, Sagal and Semaan, Karl and Chehab, Omar and Hoballah, Malak and Navani, Vishal and Gao, Yizhuo and Meyers, Daniel and Stukalin, Igor and Mittra, Arjun and Li, Mingjia and Jones, Nicholas and Grynberg, Shirly and Shapira, Ronnie and Vasbinder, Alexi and Hayek, Salim S and Bou Farhat, Elias and Eid, Marc and Saad, Eddy and Freeman, Dory and Parikh, Kaushal and Desai, Aakash and Smith, Caleb and El-Am, Edward and Nana, Frank Aboubakar and Foderaro, Simone and Baena, Javier and Herrera, Mercedes and Cortellini, Alessio and Pinato, David J and Korolewicz, James and Kim, Chul and Sackstein, Paul and Denu, Ryan A and Macaron, Walid and Abdel-Wahab, Noha and Neilan, Tomas G and Lima, João A C and Florez, Narjust and Janne, Pasi and Ricciuti, Biagio and Pecci, Federica and Choueiri, Toni K and Kwan, Jennifer M and Naqash, Abdul Rafeh},
title = {Effectiveness and safety of immunotherapy in advanced NSCLC with pericardial effusions: a global retrospective multicenter study},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {9},
doi = {10.1093/oncolo/oyag277}
}
EUVIMED